Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A side-by-side look at Sp 500 Equity and Multi Asset Retirement allocations, examining growth potential, risk, and diversification for retirement planning.
27,235 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Nvidia sits at the crossroads of AI, data centers, and gaming, powering a surge in demand that could push revenue wel...
Jim Cramer raised questions about the credibility of June payroll data amid a surge in private capital spending by te...
Nvidia Chief Executive Jensen Huang indicated the company plans to cap its OpenAI investment well below $100 billion ...
Himax (HIMX) faces a pivotal year as AR/VR, automotive displays, and smartphone drivers shape demand. This Q1 2026 ea...
Spotify is showing improving cash flow and user growth, but the stock faces FX headwinds and a lingering legal disput...
June 2026 looked like a milestone month for Oklo, but the stock went the other way. This deep dive explains why the s...
Oil prices surged this week on supply tightness and demand optimism. This note outlines the key catalysts that could ...
A family-run frozen-food business has turned nostalgia into a nationwide snack hit, shipping 20 million soup dumpling...
Jim Cramer reframes Nokia’s story from a smartphone casualty to an AI infrastructure play, highlighting the stock’s s...
Intel's stock jump last month surprised many. This article digs into the catalysts behind here's intel stock soared a...
Oscar Health is betting on a 2026 profitability turnaround after a challenging Q4 2025, highlighting AI efficiency, h...